Fangda Partners has advised WuXi XDC Cayman Inc. WuXi XDC Cayman Inc. (HK stock code: 2268) has completed a primary placement of 22,227,000 new shares at...
You must be a Standard 1 Year member to access this content.
Fangda represented HLC on the deal. Viva Biotech Holdings Group completed the equity financing at both Viva Holdings and its subsidiary Viva Biotech (Shanghai) Ltd., bringing in...
You must be a Standard 1 Year member to access this content.
Fangda advised WuXi XDC Cayman Inc. on the deal. WuXi XDC Cayman Inc. successfully spun-off from WuXi Biologics (Cayman) Inc. for a separate listing on the Main...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Huaxin Cement Co., Ltd., Fangda and Grandall advised Shenwan Hongyuan Capital (H.K.) Limited. Huaxin Cement Co., Ltd. announced its B to H Share listing...
You must be a Standard 1 Year member to access this content.
Fangda and Harneys advised Chaoju Eye Care Holdings Limited on the deal. Chaoju Eye Care Holdings raised HK$1.36 billion ($175.1 million) in net proceeds from its Hong...
You must be a Standard 1 Year member to access this content.
